Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Intra-Cellular Therapies Inc. (ITCI : NSDQ)
 
 • Company Description   
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.

Number of Employees: 512

 
 • Price / Volume Information   
Yesterday's Closing Price: $57.88 Daily Weekly Monthly
20 Day Moving Average: 1,077,640 shares
Shares Outstanding: 94.32 (millions)
Market Capitalization: $5,459.47 (millions)
Beta: 1.28
52 Week High: $66.00
52 Week Low: $28.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.82% 16.92%
12 Week 8.05% 18.77%
Year To Date 10.58% 34.77%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
430 EAST 29TH STREET
-
NEW YORK,NY 10016
USA
ph: 646-440-9333
fax: 646-440-9334
ir@intracellulartherapies.com http://www.intracellulartherapies.com
 
 • General Corporate Information   
Officers
Sharon Mates - Chief Executive officer; Chairman and President
Lawrence J. Hineline - Senior Vice President of Finance and Chief Financi
Michael Rawlins - Director
Joel S. Marcus - Director
Rory B. Riggs - Director

Peer Information
Intra-Cellular Therapies Inc. (CORR.)
Intra-Cellular Therapies Inc. (RSPI)
Intra-Cellular Therapies Inc. (CGXP)
Intra-Cellular Therapies Inc. (BGEN)
Intra-Cellular Therapies Inc. (GTBP)
Intra-Cellular Therapies Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 46116X101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 94.32
Most Recent Split Date: (:1)
Beta: 1.28
Market Capitalization: $5,459.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.80 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.89
Price/Cash Flow: -
Price / Sales: 53.05
EPS Growth
vs. Year Ago Period: -20.00%
vs. Previous Quarter: 25.71%
Sales Growth
vs. Year Ago Period: 120.41%
vs. Previous Quarter: 36.33%
ROE
03/31/22 - -53.93
12/31/21 - -54.89
09/30/21 - -44.88
ROA
03/31/22 - -47.77
12/31/21 - -48.42
09/30/21 - -40.26
Current Ratio
03/31/22 - 14.36
12/31/21 - 8.76
09/30/21 - 10.69
Quick Ratio
03/31/22 - 14.23
12/31/21 - 8.61
09/30/21 - 10.52
Operating Margin
03/31/22 - -294.89
12/31/21 - -339.04
09/30/21 - -367.06
Net Margin
03/31/22 - -294.89
12/31/21 - -339.04
09/30/21 - -367.06
Pre-Tax Margin
03/31/22 - -294.89
12/31/21 - -339.03
09/30/21 - -367.04
Book Value
03/31/22 - 8.40
12/31/21 - 5.13
09/30/21 - 5.98
Inventory Turnover
03/31/22 - 1.23
12/31/21 - 1.02
09/30/21 - 0.87
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©